Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Ethnic disparity in primary cutaneous CD30+ T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer Database.

Su C, Nguyen KA, Bai HX, Zogg CK, Cao Y, Karakousis G, Zhang PJ, Zhang G, Xiao R.

Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15222. [Epub ahead of print]

PMID:
29676444
2.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

EchevarrĂ­a-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J.

EMBO Mol Med. 2018 Apr 12. pii: e8446. doi: 10.15252/emmm.201708446. [Epub ahead of print]

3.

Disease site as a determinant of survival outcome in patients with systemic anaplastic lymphoma kinase positive anaplastic large cell lymphoma with extranodal involvement: an analysis of 1306 cases from the US National Cancer Database.

Nguyen KA, Su C, Bai HX, Zhang Z, Xiao R, Karakousis G, Zhang PJ, Zhang G.

Br J Haematol. 2018 Apr;181(2):196-204. doi: 10.1111/bjh.15145. Epub 2018 Mar 30.

PMID:
29602182
4.

Disparities in resection of hepatic metastases in colon cancer.

Neuwirth MG, Epstein AJ, Karakousis GC, Mamtani R, Paulson EC.

J Gastrointest Oncol. 2018 Feb;9(1):126-134. doi: 10.21037/jgo.2017.11.03.

5.

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.

Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford PA, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland G, Wei Z, Nathanson KL, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW.

Clin Cancer Res. 2018 Mar 21. pii: clincanres.2773.2017. doi: 10.1158/1078-0432.CCR-17-2773. [Epub ahead of print]

PMID:
29563139
6.

The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex.

Sinnamon AJ, Sharon CE, Song Y, Neuwirth MG, Elder DE, Xu X, Chu EY, Ming ME, Fraker DL, Gimotty PA, Karakousis GC.

J Am Acad Dermatol. 2018 Mar 5. pii: S0190-9622(18)30352-9. doi: 10.1016/j.jaad.2018.02.066. [Epub ahead of print]

PMID:
29518458
7.

Publication trend, resource utilization, and impact of the US National Cancer Database: A systematic review.

Su C, Peng C, Agbodza E, Bai HX, Huang Y, Karakousis G, Zhang PJ, Zhang Z.

Medicine (Baltimore). 2018 Mar;97(9):e9823. doi: 10.1097/MD.0000000000009823. Review.

8.

Histological immune response patterns in sentinel lymph nodes involved by metastatic melanoma and prognostic significance.

Abbott J, Buckley M, Taylor LA, Xu G, Karakousis G, Czerniecki BJ, Gimotty PA, Zhang PJ.

J Cutan Pathol. 2018 Feb 15. doi: 10.1111/cup.13127. [Epub ahead of print]

PMID:
29446846
9.

Comparison of Adjuvant Radiation Therapy Alone and Chemotherapy Alone in Surgically Resected Low-Grade Gliomas: Survival Analyses of 2253 Cases from the National Cancer Data Base.

Wu J, Neale N, Huang Y, Bai HX, Li X, Zhang Z, Karakousis G, Huang R, Zhang PJ, Tang L, Xiao B, Yang L.

World Neurosurg. 2018 Apr;112:e812-e822. doi: 10.1016/j.wneu.2018.01.163. Epub 2018 Jan 31.

PMID:
29409888
10.

Disease site as a determinant of survival outcome in patients with primary cutaneous peripheral T-cell lymphoma, unspecified: an analysis of 4057 cases from the US National Cancer Database.

Su C, Nguyen KA, Bai HX, Cao Y, Tao Y, Karakousis G, Zhang PJ, Zhang G, Xiao R.

Leuk Lymphoma. 2017 Dec 7:1-8. doi: 10.1080/10428194.2017.1410886. [Epub ahead of print]

PMID:
29214867
11.

Transected thin melanoma: Implications for sentinel lymph node staging.

Herbert G, Karakousis GC, Bartlett EK, Zaheer S, Graham D, Czerniecki BJ, Fraker DL, Ariyan C, Coit DG, Brady MS.

J Surg Oncol. 2018 Mar;117(4):567-571. doi: 10.1002/jso.24930. Epub 2017 Nov 30.

PMID:
29194673
12.

Surgical Management of Early-Stage Esophageal Adenocarcinoma Based on Lymph Node Metastasis Risk.

Newton AD, Predina JD, Xia L, Roses RE, Karakousis GC, Dempsey DT, Williams NN, Kucharczuk JC, Singhal S.

Ann Surg Oncol. 2018 Jan;25(1):318-325. doi: 10.1245/s10434-017-6238-z. Epub 2017 Nov 16.

PMID:
29147928
13.

Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.

Sinnamon AJ, Neuwirth MG, Gimotty PA, Gangadhar TC, Amaravadi RK, Schuchter LM, Karakousis GC.

JAMA Oncol. 2018 Jan 1;4(1):126-128. doi: 10.1001/jamaoncol.2017.3462. No abstract available.

PMID:
29145547
14.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.

Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021.

15.

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.

Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, Jiang Y, Wubbenhorst B, Amaravadi R, Bennett J, Beqiri M, Elder D, Flaherty KT, Frederick DT, Gangadhar TC, Guarino M, Hoon D, Karakousis G, Liu Q, Mitra N, Petrelli NJ, Schuchter L, Shannan B, Shields CL, Wargo J, Wenz B, Wilson MA, Xiao M, Xu W, Xu X, Yin X, Zhang NR, Davies MA, Herlyn M, Nathanson KL.

Cell Rep. 2017 Nov 14;21(7):1936-1952. doi: 10.1016/j.celrep.2017.10.052.

16.

Prophylactic Cholecystectomy at Time of Surgery for Small Bowel Neuroendocrine Tumor Does Not Increase Postoperative Morbidity.

Sinnamon AJ, Neuwirth MG, Vining CC, Sharoky CE, Yang YX, Kelz RR, Fraker DL, Roses RE, Karakousis GC.

Ann Surg Oncol. 2018 Jan;25(1):239-245. doi: 10.1245/s10434-017-6093-y. Epub 2017 Oct 24.

PMID:
29067602
17.

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.

Yam C, Xu X, Davies MA, Gimotty PA, Morrissette JJD, Tetzlaff MT, Wani KM, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas NB, Kudchadkar RR, Pavlick AC, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC.

Clin Cancer Res. 2018 Jan 1;24(1):22-32. doi: 10.1158/1078-0432.CCR-17-1807. Epub 2017 Oct 19.

PMID:
29051322
18.

Isolated Limb Perfusion and Infusion for Extremity Soft Tissue Sarcoma: A Contemporary Systematic Review and Meta-Analysis.

Neuwirth MG, Song Y, Sinnamon AJ, Fraker DL, Zager JS, Karakousis GC.

Ann Surg Oncol. 2017 Dec;24(13):3803-3810. doi: 10.1245/s10434-017-6109-7. Epub 2017 Oct 11.

PMID:
29022281
19.

Comparison of chemoradiotherapy with radiotherapy alone for early-stage extranodal natural killer/T-cell lymphoma, nasal type in elderly patients.

Su C, Nguyen KA, Bai HX, Balaji D, Cao Y, Karakousis G, Zhang PJ, Zhang G, Xiao R.

Leuk Lymphoma. 2017 Oct 5:1-7. doi: 10.1080/10428194.2017.1379078. [Epub ahead of print]

PMID:
28980517
20.

Comparison of chemoradiotherapy with radiotherapy alone for "biopsy only" anaplastic astrocytoma.

Wu J, Zou T, Bai HX, Li X, Zhang Z, Xiao B, Nasrallah M, Karakousis G, Cao Y, Zhang PJ, Yang L.

Oncotarget. 2017 Apr 26;8(40):69038-69046. doi: 10.18632/oncotarget.17441. eCollection 2017 Sep 15.

21.

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W.

Nature. 2017 Oct 5;550(7674):133-136. doi: 10.1038/nature24040. Epub 2017 Sep 27.

22.

An Update on Randomized Clinical Trials in Melanoma.

Karakousis G, Ariyan C.

Surg Oncol Clin N Am. 2017 Oct;26(4):559-586. doi: 10.1016/j.soc.2017.05.002. Review.

PMID:
28923220
23.

Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.

Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, Filisio F, Giles-Davis W, Xu X, Karakousis GC, Schuchter LM, Xu W, Amaravadi R, Xiao M, Sadek N, Krepler C, Herlyn M, Freeman GJ, Rabinowitz JD, Ertl HCJ.

Cancer Cell. 2017 Sep 11;32(3):377-391.e9. doi: 10.1016/j.ccell.2017.08.004.

PMID:
28898698
24.

Trends in major upper abdominal surgery for cancer in octogenarians: Has there been a change in patient selection?

Neuwirth MG, Bierema C, Sinnamon AJ, Fraker DL, Kelz RR, Roses RE, Karakousis GC.

Cancer. 2018 Jan 1;124(1):125-135. doi: 10.1002/cncr.30977. Epub 2017 Sep 7.

PMID:
28881379
25.

Understanding readmissions following operations of the thyroid and parathyroid glands.

Collier K, Sataloff J, Wirtalla C, Kuo L, Karakousis GC, Kelz RR.

Am J Surg. 2017 Sep;214(3):501-508. doi: 10.1016/j.amjsurg.2017.01.008. Epub 2017 Jan 10.

PMID:
28818283
26.

Hospitalization in the Year Preceding Major Oncologic Surgery Increases Risk for Adverse Postoperative Events.

Sharoky CE, Collier KT, Wirtalla CJ, Sinnamon AJ, Neuwirth MG, Kuo LE, Roses RE, Fraker DL, Karakousis GC, Kelz RR.

Ann Surg Oncol. 2017 Nov;24(12):3477-3485. doi: 10.1245/s10434-017-6032-y. Epub 2017 Aug 14.

PMID:
28808930
27.

Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.

Gangadhar TC, Savitch SL, Yee SS, Xu W, Huang AC, Harmon S, Lieberman DB, Soucier D, Fan R, Black TA, Morrissette JJD, Salathia N, Waters J, Zhang S, Toung J, van Hummelen P, Fan JB, Xu X, Amaravadi RK, Schuchter LM, Karakousis GC, Hwang WT, Carpenter EL.

Pigment Cell Melanoma Res. 2018 Jan;31(1):73-81. doi: 10.1111/pcmr.12623. Epub 2017 Oct 23.

PMID:
28786531
28.

Does Surgeon Sex Matter?: Practice Patterns and Outcomes of Female and Male Surgeons.

Sharoky CE, Sellers MM, Keele LJ, Wirtalla CJ, Karakousis GC, Morris JB, Kelz RR.

Ann Surg. 2017 Jul 24. doi: 10.1097/SLA.0000000000002460. [Epub ahead of print]

PMID:
28742695
29.

Association Between Patient Age and Lymph Node Positivity in Thin Melanoma.

Sinnamon AJ, Neuwirth MG, Yalamanchi P, Gimotty P, Elder DE, Xu X, Kelz RR, Roses RE, Chu EY, Ming ME, Fraker DL, Karakousis GC.

JAMA Dermatol. 2017 Sep 1;153(9):866-873. doi: 10.1001/jamadermatol.2017.2497.

PMID:
28724122
30.

Predictors of false negative sentinel lymph node biopsy in trunk and extremity melanoma.

Sinnamon AJ, Neuwirth MG, Bartlett EK, Zaheer S, Etherington MS, Xu X, Elder DE, Czerniecki BJ, Fraker DL, Karakousis GC.

J Surg Oncol. 2017 Dec;116(7):848-855. doi: 10.1002/jso.24743. Epub 2017 Jun 26.

PMID:
28650537
31.

Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database.

Su C, Nguyen KA, Bai HX, Cao Y, Tao Y, Xiao R, Karakousis G, Zhang PJ, Zhang G.

J Am Acad Dermatol. 2017 Sep;77(3):497-502.e2. doi: 10.1016/j.jaad.2017.04.1137. Epub 2017 Jun 20.

PMID:
28645647
32.

Adjuvant chemotherapy in resectable synovial sarcoma.

Vining CC, Sinnamon AJ, Ecker BL, Kelz RR, Fraker DL, Roses RE, Karakousis GC.

J Surg Oncol. 2017 Sep;116(4):550-558. doi: 10.1002/jso.24688. Epub 2017 Jun 5.

PMID:
28580620
33.

Contemporary reappraisal of the efficacy of adjuvant chemotherapy in resected retroperitoneal sarcoma: Evidence from a nationwide clinical oncology database and review of the literature.

Datta J, Ecker BL, Neuwirth MG, Geha RC, Fraker DL, Roses RE, Karakousis GC.

Surg Oncol. 2017 Jun;26(2):117-124. doi: 10.1016/j.suronc.2017.01.008. Epub 2017 Feb 2. Review.

PMID:
28577717
34.

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ.

Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.

35.

Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.

Ecker BL, McMillan MT, Datta J, Lee MK, Karakousis GC, Vollmer CM Jr, Drebin JA, Fraker DL, Roses RE.

Cancer. 2017 May 15;123(6):967-976. doi: 10.1002/cncr.30439. Epub 2016 Nov 7.

PMID:
28263387
36.

Development and validation of a prediction model for patients discharged to post-acute care after colorectal cancer surgery.

Bailey EA, Hoffman RL, Wirtalla C, Karakousis G, Kelz RR.

Surgery. 2017 Apr;161(4):1049-1057. doi: 10.1016/j.surg.2016.10.015. Epub 2016 Dec 3.

PMID:
27919450
37.

Lymph node evaluation and survival after curative-intent resection of duodenal adenocarcinoma: A matched cohort study.

Ecker BL, McMillan MT, Datta J, Dempsey DT, Karakousis GC, Fraker DL, Drebin JA, Mamtani R, Giantonio BJ, Roses RE.

Eur J Cancer. 2016 Dec;69:135-141. doi: 10.1016/j.ejca.2016.09.027. Epub 2016 Nov 4.

PMID:
27821316
38.

Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis.

Karakousis G, Gimotty PA, Bartlett EK, Sim MS, Neuwirth MG, Fraker D, Czerniecki BJ, Faries MB.

Ann Surg Oncol. 2017 Apr;24(4):952-959. doi: 10.1245/s10434-016-5646-9. Epub 2016 Nov 2.

39.

Implications of Lymph Node Evaluation in the Management of Resectable Soft Tissue Sarcoma.

Ecker BL, Peters MG, McMillan MT, Sinnamon AJ, Zhang PJ, Kelz RR, Roses RE, Drebin JA, Fraker DL, Karakousis GC.

Ann Surg Oncol. 2017 Feb;24(2):425-433. doi: 10.1245/s10434-016-5641-1. Epub 2016 Oct 26.

PMID:
27785659
40.

Obesity is not associated with increased morbidity in patients undergoing cytoreductive surgery with intraperitoneal chemotherapy.

Neuwirth MG, Bartlett EK, Roses RE, Fraker DL, Kelz RR, Karakousis GC.

J Surg Oncol. 2016 Oct;114(5):619-624. doi: 10.1002/jso.24366. Epub 2016 Jul 7.

PMID:
27383501
41.

A prognostic model for resectable soft tissue and cutaneous angiosarcoma.

Sinnamon AJ, Neuwirth MG, McMillan MT, Ecker BL, Bartlett EK, Zhang PJ, Kelz RR, Fraker DL, Roses RE, Karakousis GC.

J Surg Oncol. 2016 Oct;114(5):557-563. doi: 10.1002/jso.24352. Epub 2016 Jul 4.

PMID:
27378102
42.

Preoperative radiotherapy in the management of retroperitoneal liposarcoma.

Ecker BL, Peters MG, McMillan MT, Sinnamon AJ, Zhang PJ, Fraker DL, Levin WP, Roses RE, Karakousis GC.

Br J Surg. 2016 Dec;103(13):1839-1846. doi: 10.1002/bjs.10305. Epub 2016 Sep 29.

PMID:
27682864
43.

Morbidity and mortality after total splenectomy for lymphoid neoplasms.

Neuwirth MG, Bartlett EK, Newton AD, Fraker DL, Kelz RR, Roses RE, Karakousis GC.

J Surg Res. 2016 Sep;205(1):155-62. doi: 10.1016/j.jss.2016.06.031. Epub 2016 Jun 17.

PMID:
27621013
44.

The role of body mass index class in cholecystectomy after acute cholecystitis: An American College of Surgeons National Surgical Quality Improvement Program analysis.

Neylan CJ, Damrauer SM, Kelz RR, Farrar JT, Dempsey DT, Lee MK 4th, Karakousis GC, Tewksbury CM, Pickett-Blakely OE, Williams NN, Dumon KR.

Surgery. 2016 Sep;160(3):699-707. doi: 10.1016/j.surg.2016.05.012. Epub 2016 Jul 15.

PMID:
27425042
45.

Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Sep 8;537(7619):254. doi: 10.1038/nature18939. Epub 2016 Jul 6. No abstract available.

PMID:
27383789
46.

Oncogenic BRAF-Mediated Melanoma Cell Invasion.

Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, Schuchter LM, Field J, Zhang PJ, Herlyn M, Xu X, Guo W.

Cell Rep. 2016 May 31;15(9):2012-24. doi: 10.1016/j.celrep.2016.04.073. Epub 2016 May 19.

47.

Acral Lentiginous Histologic Subtype and Sentinel Lymph Node Positivity in Thin Melanoma.

Marek AJ, Ming ME, Bartlett EK, Karakousis GC, Chu EY.

JAMA Dermatol. 2016 Jul 1;152(7):836-7. doi: 10.1001/jamadermatol.2016.0875. No abstract available.

48.

Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States.

Datta J, McMillan MT, Ruffolo L, Lowenfeld L, Mamtani R, Plastaras JP, Dempsey DT, Karakousis GC, Drebin JA, Fraker DL, Roses RE.

Ann Surg Oncol. 2016 Sep;23(9):2936-45. doi: 10.1245/s10434-016-5224-1. Epub 2016 Apr 18.

PMID:
27090793
49.

The state of melanoma: challenges and opportunities.

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA.

Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16. doi: 10.1111/pcmr.12475. Epub 2016 Apr 17.

50.

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.

Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M.

J Clin Invest. 2016 May 2;126(5):1834-56. doi: 10.1172/JCI82661. Epub 2016 Apr 4.

Supplemental Content

Loading ...
Support Center